David Cordas dos Santos
@DavidCdSMD
Clinician-Scientist from Munich | Postdoc at Dana-Farber Cancer Institute
Check out our new study in @NatureMedicine looking at nonrelapse mortality after CAR-T cell treatment with Tobias Tix and @KRejeski nature.com/articles/s4159…
What a privilege to present my research at the @WMIWMF Educational Forum last weekend. Thank you for supporting my work and hosting such a fantastic event. The patients’ feedback was truly encouraging. Excited to dive deeper into spatial Waldenström biology!
So excited to see this work out in print! Congratulations to the whole team, and especially @JbAlberge , for this masterpiece!
1/ 🧵Check out our new study in @NatureGenet, which examines how precancerous conditions (MGUS/SMM) evolve into Multiple Myeloma, and offers new computational methods to predict progression risk and model cancer evolution. doi.org/10.1038/s41588…
A must read if you are heading to the #AACR25 session on CAR-T Cells in Hematological Malignancies: Innovations and Pitfalls from @KRejeski @MSKCancerCenter. brnw.ch/21wSePV
The latest in a trio of meta-analyses led by @TobiasTix, @DavidCdSMD & @KRejeski just out at @MolTherapy on non-relapse mortality after bispecific Ab in lymphoma & myeloma. >70% of non-relapse deaths are due to infection - Must prioritise measurement, reporting, prophylaxis
What happens beyond response? Our new study explores non-relapse mortality in patients with lymphoma and myeloma receiving bispecific antibodies. @KRejeski walks you through the key points:
Excited to share the first paper from the new lab 🎉 What drives nonrelapse mortality with bispecific antibody therapy in myeloma and lymphoma? Led by the incredibly talented @tix_tobi w/big thanks also to @DavidCdSMD Check it out in @MolTherapy 👇 cell.com/molecular-ther…
Focus on NRMs and SPMs @Myeloma_Society . First, a meta-analysis presented by Dr. Cordas dos Santos from DFCI highlight the impact of that infections and SPMs were the first and second causes of NRMs, with SPMs standing at 7-8% #mms
Fantastic work by @SophiaStock_ on our @LMU_Immutherapy @LMU_Uniklinikum study delineating the prognostic significance of immune reconstitution (IR) in CAR-T recipients - out today in @Hemasphere_EHA Check out open access link 👇 onlinelibrary.wiley.com/doi/full/10.10…
Bone Marrow Spatial Signatures Predict Outcomes in CAR-T Patients ... youtu.be/USr0RCn9jJ0?si… @DanaFarber #MMsm #ASH24 #HealthTree #myeloma
CONGRESS | #ASH24 | Kai Rejeski @KRejeski @MSKCancerCenter discusses pre-apheresis prediction of response and toxicity for pts receiving BCMA-targeted CAR-T for RRMM. High pre-apheresis HT scores are linked to poor-risk features, and combining these scores with MM-specific HR…
Great work by Yoshi and David on spatial proteomics on bone marrow pre and post CART #ash24 #mmsm
Kudos to @IrenemGhobrial @LabGhobrial for the amazing work presented at #ASH24 Always pushing technology to the next level and bringing new insight in myeloma #mmsm My favorite: the use of imaging mass cytometry to understand CRS, hematotoxicity and survival after CAR T therapy
Can we predict toxicity and response before apheresis - so at a clinically actionable time - in BCMA CAR-T recipients with RRMM? 👉 Utility of the CAR HEMATOTOX for early tox prediction 👉 Identification of ultra high risk pts (1 yr PFS 20%) when combining with MM specific RF
ash.confex.com/ash/2024/webpr… by @IrenemGhobrial spatially defined “bad players” (MDSCs, M2 macrophages, exhausted T cells) predict for worse outcomes post-CART #ASH24 /10
NEW content online! New horizons in our understanding of precursor multiple myeloma and early interception go.nature.com/3Ae6WVg
Check out our new article in @NatureRevCancer where we take a deep dive into early myeloma and discuss the potential of T cell-redirecting therapies! nature.com/articles/s4156… @IrenemGhobrial @JbAlberge @LucaBertamini and Rosa Toenges @DanaFarberNews #mmsm
So thrilled to be a part of @NCIHTAN! Looking forward to exciting collaborations and projects in the spatial field!
Congrats to @IrenemGhobrial, @DavidCdSMD and the Ghobrial Lab at @DanaFarber for being awarded a NIH/NCI Human Tumor Atlas Network grant. Their work on the Multidimensional Myeloma Pre-Cancer Atlas will help map disease progression in multiple myeloma. ms.spr.ly/6018mWIig
Thanks @TheCancerLetter for the chance to comment on excellent work by @KRejeski @DrMiguelPerales @RShouval et al in @CCR_AACR 💪 Many theories we've postulated for why CAR-T recipients may appear to be at ⬆️ SPM risk - now we have data to back this up! aacrjournals.org/clincancerres/…
Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows. cancerletter.com/clinical/20240…
Our next paper on second primary malignancies after CAR-T treatment is out in @CCR_AACR ! 🙌🏻 Awesome teamwork with @KRejeski and @ttix09!
Excited to share our new paper focusing on Second Primary Malignancies (SPMs) following CAR T-cell therapy out today in @CCR_AACR ! 👇 This first-in-kind meta-analysis spans 5,517 lymphoma and myeloma patients receiving a range of CAR-T products. aacrjournals.org/clincancerres/…
One of many benefits being a researcher is making friends with highly talented people and visiting them around the world. Last weekend was a blast! Thanks and congrats to @LucaBertamini! With @JbAlberge
Infections account for about half of all non-relapse-related deaths after #CARTcelltherapy, underscoring the necessity for clinical risk-mitigating strategies. News & Views from @MarcelaMaus and @vikblumenberg @MGHCancerCenter nature.com/articles/s4159…